Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn

New England Journal of Medicine

Volumn 354, Issue 6, 2006, Pages 579-587

  Chambers, Christina D ^a,b   Hernandez Diaz, Sonia ^c   Van Marter, Linda J ^d   Werler, Martha M ^c   Louik, Carol ^c   Jones, Kenneth Lyons ^a   Mitchell, Allen A ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOSTON UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; FLUOXETINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; INFANT; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPOTONIA; NERVOUSNESS; NEWBORN; NURSE; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; RISK FACTOR; SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER; FEMALE; FETUS; HUMANS; INFANT, NEWBORN; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PERSISTENT FETAL CIRCULATION SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 32144436098     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa052744     Document Type: Article

References (34)

1. Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin Perinatol 2005;29:8-14.
2. John E, Roberts V, Burnard E. Persistent pulmonary hypertension of the newborn treated with hyperventilation: clinical features and outcome. Aust Paediatr 1988;24:357-61.
3. Hageman JR, Adams MA, Gardner TH. Persistent pulmonary hypertension of the newborn: trends in incidence, diagnosis, and management. Am J Dis Child 1984;138:592-5.
4. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105:14-20.
5. Fricker J. Nitric oxide may reduce need for extracorporeal membrane oxygenation. Lancet 1996;347:1397.
6. Van Marter LJ, Leviton A, Allred EN, et al. Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal anti-inflammatory drug consumption during pregnancy. Pediatrics 1996;97:658-63.
7. Abman SH. New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. Pediatr Pulmonol Suppl 1999;18:201-4.
8. Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 2005;39:492-503.
9. Reece EA, Moya F, Yazigi R, et al. Persistent pulmonary hypertension: assessment of perinatal risk factors. Obstet Gynecol 1987;70:696-700.
10. Bearer C, Emerson RK, O'Riordan MA, Roitman E, Shackleton C. Maternal tobacco smoke exposure and persistent pulmonary hypertension of the newborn. Environ Health Perspect 1997;105:202-6.
11. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5.
12. Mitchell AA, Rosenberg L, Shapiro S, Slone D. Birth defects related to Bendectin use in pregnancy. I. Oral clefts and cardiac defects. JAMA 1981;245:2311-4.
13. Hasler G, Pine DS, Gamma A, et al. The associations between psychopathology and being overweight: a 20-year prospective study. Psychol Med 2004;34:1047-57.
14. Wisner KL, Gelenberg AJ, Leonard H, Zarin D, Frank E. Pharmacologic treatment of depression during pregnancy. JAMA 1999;282:1264-9.
15. Suhara T, Sudo Y, Yoshida K, et al. Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet 1998;351:332-5.
16. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985;46:14-9.
17. McMahon TJ, Hood JS, Nossaman BD, Kadowitz PJ. Analysis of responses to serotonin in the pulmonary vascular bed of the cat. J Appl Physiol 1993;75:93-102.
18. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361:1533-44.
19. Eddahibi S, Raffestin B, Hamon M, Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med 2002;139:194-201.
20. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999;42:2561-8.
21. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996;32:653-8.
22. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90:288-91.
23. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-32.
24. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312-6.
25. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368-75.
26. Laine K, Kytola J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit 2004;26:685-7.
27. Sanz EJ, De-las-Cuevas C, Kiunu K, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482-7.
28. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-83.
29. Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670-6.
30. Hernan MA, Hernandez-Diaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 2002;155:176-84.
31. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994;151:979-86.
32. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-44.
33. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398-407.
34. Moses-Kolko EL, Roth EK. Antepartum and postpartum depression: healthy mom, healthy baby. J Am Med Womens Assoc 2004;59:181-91.